BioSpectrum the business of Bio & Health Sciences ASIA EDITION

TVM Capital Healthcare announces $35 M investment into Boston Oncology Arabia

June 26, 2024 | News

Boston Oncology Arabia is contributing to a key goal of Saudi Arabia's Vision 2030 by supplying critical care medicines



TVM Capital Healthcare, an international healthcare expansion and growth capital firm, has announced a $35 million investment in Boston Oncology Arabia, a bio-generic drugs manufacturing company based in the Kingdom of Saudi Arabia.

From its headquarters in Riyadh and production facility in Sudair Industrial City, Boston Oncology Arabia provides vital medicines for critical conditions through the local development and manufacturing of internationally licensed, best-in-class therapeutics.

Saudi Arabia’s growing demand for locally manufactured, life-saving specialty drug treatments positions the company to become one of the Kingdom’s key providers of specialty generics and biosimilar medications. By using already approved formulations, Boston Oncology Arabia meets the highest standards of pharmaceutical quality, safety, and efficacy.

Boston Oncology Arabia is contributing to a key goal of Saudi Arabia’s Vision 2030 by supplying critical care medicines through highly flexible, local manufacturing facilities and leveraging its international relationships for licensing from Western and Eastern markets.

With extensive operating experience in the Middle East, TVM Capital Healthcare’s involvement will expedite Boston Oncology Arabia’s move into full formulation and fill and finish manufacturing at its local production facility in Sudair Industrial City. The firm will also provide strategic support and leverage its global network to further expand the company’s access to international suppliers.